PROGRAMMATIC GROWTH

GRAIL Trial


Our partnership with GRAIL, a life sciences company devoted to the early detection of cancer, allows us to provide patients access to the Circulating Cell-Free Genome Atlas (CCGA) study.

This observational study, comprised of individuals both with and without cancer, will analyze specific nucleic acids in the blood that are emerging as biomarkers for early cancer detection.

The five-year study will provide a detailed atlas of cancer genetics that GRAIL will use to support the development of blood tests and other tools that can help find cancer before symptoms appear.

"This is a great opportunity for local Cincinnatians to make a difference in the fight against cancer," said Philip Leming, MD, principal investigator of the CCGA study and medical oncologist at The Christ Hospital Health Network.